67例结肠癌DNA倍体和Ag—NOR计数分析对判断患者预后价值的初步探讨

A preliminary study of DNA ploidy and Ag-NOR counts on the prognostic evaluation of67 patients with colonic cancer

对６７例结肠癌石蜡包埋组织材料做ＤＮＡ倍体水平分析和Ａｇ—ＮＯＲ计数。结果见：ＤＮＡ二倍体肿瘤５年、７年生存率分别为７８．０％（３２／４１）、３９．０％（１６／４１）；非二倍体肿瘤则为２６．９％（７／２６）、１１．５％（３／２６）（ｐ＜０．０１、ｐ＜０．０５）；Ａｇ─ＮＯＲ计数小于均值（６．９±１．０）组５年、７年生存率为８０．０％（２８／３５）、４０．０（１４／３５），大于均值组则为３４．４％（１１／３２）、１５．６％（５／３２）（ｐ＜０．０１、ｐ＜０．０５）。Ａｇ－ＮＯＲ计数小于均值组ＤＮＡ二倍体肿瘤占９７．１％（３４／３５）；大于均值组二倍体肿瘤占２１．９％（７／３２）（ｐ＜０．０１）。结果表明：ＤＮＡ倍体水平和Ａｇ－ＮＯＲ计数具有一致性，可以做为判断结肠癌预后指标。

Flow cytometry (FCM) and silver colloid staining technique have special valve for retrospective analyses of the tumors. The DNA ploidy and Ag-NOR counts in 67 paraffin-embeded samples were analyzed, 5 or 7-year survival rate was 78. 0% (32/41 )and 39. 0% (16/41 )for the patients with DNA diploid tumor,while 26. 9% (7/26)and 11. 5% (3/26) for the patients with DNAnon -diploid trmor (p<0.01 and p<0. 05 respectively). The survival percentage at 5 or 7 yearswas 80. 0%(28/35) and 40. 0% (14/35) for the patients with Ag-NOR counts less than X±SD6.9±1. 0,while 34. 4(11/32) and 15. 6% (5/32) for those with Ag-NOR counts more than that(p<0. 01 and p<0. 05 respectively). DNA ploidy and Ag-NOR counts were closely related toprognostic factors of colonic cancer. DNA diploid was 97. 7K (34/35) for the patients with AgNOR counts less than the mean of 6. 9±1. 0,while 21. 9% (7/32) for the patients with Ag-NORcounts more than that (p<0. 01 ). These findings suggest that DNA ploidy and Ag-NOR counts be considered as prognostic parameters of colonic cancer.